ÈESKÁ UROLOGIE / CZECH UROLOGY – 1 / 2018

25 Ces Urol 2018; 22(1): 14–26 PØEHLEDOVÝ ÈLÁNEK 4. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: 725–732. 5. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981–990. 6. Jacobsen SJ, Katusic SK, Bergstrahl EJ, et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA 1995; 274: 1445–1449. 7. Kim EH, Andriole GL. Prostate-specific antigen-based screening: controversy and guidelines. BMC Med 2015; 13: 61. 8. Stanford JL, Stephenson RA, Coyle LM, et al. Prostate cancer trends 1973–1995, SEER program, national cancer institute. Bethesda, MD: NIH; 1999: pub 99–4543. 9. Wasserbauer R. Aktivní pøístup k èasné detekci karcinomu prostaty – co je smysluplné a co již škodlivé. Urol List 2014; 12(2): 19–28. 10. Belej K. Screening karcinomu prostaty. Onkologie 2009; 3(6): 351–356. 11. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA Guideline. J Uol 2013; 190: 419–426. 12. Moyer VA. U.S. Preventive services task force. Screening for prostate cancer: U.S. Preventive services task force recommendation statement. Ann Intern Med 2012; 157: 120–134. 13. Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1797. 14. Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61: 1079–1092. 15. Lima CA, Silva AM, Kuwano AY, Rangel MR, Macedo-Lima M. Trends in prostate cancer incidence and mortality in a mid-sized Northeastern Brazilian city. Ver Assoc Med Bras 2013; 59: 15–20. 16. https://seer.cancer.gov/registries/list.html. 17. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev 2013; 1: CD004720. 18. Shteynshlyuger A, Andriole GL. Prostate cancer: to screen or not to screen? Urol Clin North Am 2010; 37: 1–9. 19. Etzioni R, Gulati R, Falcon S, Penson DF. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making 2008; 28: 323–331. 20. Crawford ED, Abrahamsson PA. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests? Eur Urol 2008; 54: 262–273. 21. Welsh HG, Gorski DH, Albertsen PC. Trends in metatatic breast and prostate cancer – lessons in cancer dynamics. N Engl J Med 2015; 373: 1685–1687. 22. Lilja H, Cronin AM, Dahlin A, et al. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 2011; 117: 1210–1219. 23. Vickers AJ, Ulmert D, Sjoberg DD, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40–55 and long term risk of metastasis: case-control study. BMJ 2013; 346: f2023. 24. Pena SD, Di Pietro G, Fuchshuber-Moraes M, et al. The genomic ancestry o individuals from different geographic regions of Brazil is more uniform than expected. PLoS One 2011; 6: e17063. 25. Heidenreich A, Abrahmsson PA, Artibani W, et al. Early detection of prostate cancer: European As- sociation of Urology recommendation. Eur Urol 2013; 64: 347–354. 26. Holmstrom B, Johansson M, Bergh A, et al. Prostate specific antigen for early detection of prostate cancer: longitudinal study. BMJ 2009; 339: b3537.